Internal dosimetry studies of 170Tm-EDTMP complex, as a bone pain palliation agent, in human tissues based on animal data

Shirmardi, Seyed Pezhman; Saniei, Elham; Das, Tapas; Noorvand, M.; Erfani, Mostafa; Bagheri, Reza

doi:10.1016/j.apradiso.2020.109396

Cited by 3 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further preclinical work towards the implementation of 170 Tm in bone pain palliation applications has been undertaken by radiolabelling a series of both cyclic and acyclic polyaminophosphonic acid-based chelators, namely EDTMP, diethylenetriaminepentamethylenephosphonic acid (DTPMP), triethylenetetraminehexamethylenephosphonic acid (TTHMP), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP) and 1,4,8,11-tetraazacyclotetradecane-1–4-8–11-tetramethylenephosphonic acid (CTMP) (see Fig. 12 ) (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ). Dosimtery, biodistribution, pharmacokinetic, scinitigraphic and SPECT imaging studies of these radiolabelled compounds have given a preponderance of promising preclinical data indicating the significant potential for 170 Tm as a theranostic probe for bone pain palliation arising from various cancers metastasising to the skeleton (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ).…”

Section: Thulium: 170 Tmmentioning

confidence: 99%

“…12 ) (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ). Dosimtery, biodistribution, pharmacokinetic, scinitigraphic and SPECT imaging studies of these radiolabelled compounds have given a preponderance of promising preclinical data indicating the significant potential for 170 Tm as a theranostic probe for bone pain palliation arising from various cancers metastasising to the skeleton (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ). In one study, 170 Tm was prepared using a 169 Tm 2 (NO 3 ) 3 target and a neutron flux of 3–4 × 10 13 n/cm 2 /s for 5 days, resulting in a final formulation with adequate specific activity and radiopurity (> 99.99%) suitable for subsequent radiolabelling EDTMP with a yield of > 99% and high in vitro stability (> 95% after two months incubation at RT).…”

Section: Thulium: 170 Tmmentioning

confidence: 99%

“…More recently, however, [ 170 Tm]Tm-EDTMP has attracted more considerable research attention. Further preclinical studies and preliminary clinical investigations have afforded results that are indicative of the significant future potential of [ 170 Tm]Tm-EDTMP as a theranostic agent in bone pain palliation (Shirmardi et al 2020 ; Das et al 2017 ). One illustrative example is the efficacy evaluation of a freeze-dried EDTMP kit for the in-house preparation of [ 170 Tm]Tm-EDTMP which has provided encouraging results (Das et al 2017 ).…”

Section: Thulium: 170 Tmmentioning

confidence: 99%

See 2 more Smart Citations

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.

show abstract

Section: Thulium: 170 Tmmentioning

confidence: 99%

Section: Thulium: 170 Tmmentioning

confidence: 99%

Section: Thulium: 170 Tmmentioning

confidence: 99%

See 1 more Smart Citation

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…Based on the animal phantoms, specific absorbed fractions, S-values and absorbed doses of several radionuclides have been calculated by the use of MC software, such as EGS, MCNP, GAMOS, GATE, etc. (11)(12)(13) . However, as is known, long simulation time is the limit for MC method.…”

Section: Introductionmentioning

confidence: 99%

Voxel-based dose calculation of radionuclide imaging and therapy for preclinical studies using GEANT4 Monte Carlo simulation

Liu

Geng²,

Tang³

et al. 2022

Int J Radiat Res

View full text Add to dashboard Cite

Background: This study aims to investigate voxel-level dose calculation methods and improve its calculation efficiency in nuclear medicine that can consider animal-specific heterogeneous tissue compositions and radiopharmaceutical biodistributions simultaneously. Materials and Methods: The voxelized mouse phantom was constructed from real mouse CT images and simulated using the Monte Carlo GEANT4 code. According to the dynamic PET images of real mouse, the real distribution of radiopharmaceutical activity was set in the Monte Carlo simulation. The sampling method to improve the calculation efficiency was proposed. Two voxel-level dose calculation methods were implemented in this study. The average absorbed dose in vital target organs and the tumor was calculated by the proposed voxel-level dose calculation methods and the traditional MIRD method respectively. The results of the average absorbed dose calculated by the two methods were compared. Based on the voxel-level dose calculation method, the three-dimensional dose distribution in organs and the tumor was obtained and evaluated. Results: The relative difference of average absorbed dose between the two voxel-level dose calculation methods was mostly less than 10%. The sampling method proposed to improve calculation efficiency for the voxel-level dose calculation can decrease the calculation time by ~34% with less deviation. Conclusion: The results confirmed that the voxel-level dose calculation methods proposed in this study allow for more accurate and efficient assessment of the internal radiation dose.

show abstract

177Lu-EDTMP radiation absorbed dose evaluation in man based on biodistribution data in Wistar rats

Bagheri¹

2023

Nuclear Engineering and Technology

View full text Add to dashboard Cite

Internal dosimetry studies of 170Tm-EDTMP complex, as a bone pain palliation agent, in human tissues based on animal data

Cited by 3 publications

References 35 publications

Cutting edge rare earth radiometals: prospects for cancer theranostics

Cutting edge rare earth radiometals: prospects for cancer theranostics

Voxel-based dose calculation of radionuclide imaging and therapy for preclinical studies using GEANT4 Monte Carlo simulation

177Lu-EDTMP radiation absorbed dose evaluation in man based on biodistribution data in Wistar rats

Contact Info

Product

Resources

About